pentoxifylline has been researched along with Cutaneous T-Cell Lymphoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rishi, L | 2 |
| Gahlot, S | 2 |
| Kathania, M | 1 |
| Majumdar, S | 2 |
| Khan, MA | 1 |
| Stoopler, ET | 1 |
| Musbah, T | 1 |
| Weiss, JM | 1 |
| Vanscheidt, W | 1 |
| Pilarski, KA | 1 |
| Weyl, A | 1 |
| Peschen, M | 1 |
| Schöpf, E | 1 |
| Vestweber, D | 1 |
| Simon, JC | 1 |
4 other studies available for pentoxifylline and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Pentoxifylline induces apoptosis in vitro in cutaneous T cell lymphoma (HuT-78) and enhances FasL mediated killing by upregulating Fas expression.
Topics: Apoptosis; Cell Line, Tumor; Cells, Cultured; Fas Ligand Protein; fas Receptor; Gene Expression Regu | 2009 |
Pentoxifylline augments TRAIL/Apo2L mediated apoptosis in cutaneous T cell lymphoma (HuT-78 and MyLa) by modulating the expression of antiapoptotic proteins and death receptors.
Topics: Adjuvants, Pharmaceutic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Drug Synergism; | 2010 |
Recurrent aphthous stomatitis.
Topics: Administration, Oral; Adult; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male; Pentoxify | 2013 |
Pentoxifylline inhibits tumor necrosis factor-alpha (TNF alpha)-induced T-lymphoma cell adhesion to endothelioma cells.
Topics: Animals; Cell Adhesion; Cell Line; Lymphangioma; Lymphoma, T-Cell, Cutaneous; Mice; Pentoxifylline; | 1995 |